98%
921
2 minutes
20
Background: Affective symptoms are a prevalent psychopathological feature in various psychiatric disorders. However, the underlying neurobiological mechanisms are complex and not yet fully understood.
Methods: We used normative modeling to establish a reference for functional activation of functional magnetic resonance imaging based on an emotional episodic memory task, which is frequently used to study affective symptoms in psychiatric disorders. This normative reference was derived from a large dataset of healthy individuals ( = 409) and used to evaluate individualized functional alterations by calculating deviations from this reference in a clinical dataset, which included 164 healthy control participants and patients with major depressive disorder (MDD) ( = 56), bipolar disorder (BD) ( = 31), and schizophrenia (SZ) ( = 73). The functional deviations were mapped to emotional networks (ENs) with specific emotional functions and used to predict affective symptoms in different mental disorders. The microscale cellular signatures underlying macroscale variations were identified using imaging transcriptomic analysis and associated with affective symptoms.
Results: We observed distinct patterns of cross-scale neural alterations linked to affective symptoms in 3 psychiatric disorders. Macroscale neural dysfunctions in distinct disorders were embedded into non-overlapping ENs and significantly associated with affective symptoms. Oligodendrocytes may mediate the network-specific impairments and microglia for MDD, astrocytes for BD, and excitatory neurons for SZ as replicable cell-type correlates of affective symptoms.
Conclusions: These findings revealed cross-scale neural alterations underlying affective symptoms in psychiatric disorders, providing a basis for understanding their neuropathological patterns and guiding individualized treatment.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240089 | PMC |
http://dx.doi.org/10.1016/j.bpsgos.2025.100534 | DOI Listing |
Alzheimers Dement
September 2025
School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, New South Wales, Australia.
Introduction: Risperidone is approved for behaviors and psychological symptoms of dementia (BPSD), despite modest efficacy and known risks. Identifying responsive symptoms, treatment modifiers, and predictors is crucial for personalized treatment.
Method: A one-stage individual participant data meta-analysis of six randomized controlled trials (risperidone: n = 1009; placebo: N = 712) was conducted.
Neurosci Biobehav Rev
September 2025
Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milano, Italy; University Vita-Salute San Raffaele, Milano, Italy.
Machine learning (ML) could be useful in identifying reliable predictors of treatment response in affective and not affective psychoses, potentially helping to propose personalized interventions. In this systematic review and meta-analysis, we evaluated studies exploiting ML algorithms to predict the improvement of psychotic symptoms, cognition and quality of life in psychoses related to different treatments. We searched MEDLINE (PubMed), Web of Science, and PsycINFO databases updated until February 2024, identifying 64 articles published in English in peer-reviewed journals.
View Article and Find Full Text PDFEur Arch Psychiatry Clin Neurosci
September 2025
Department of Psychiatry, University of Pittsburgh, 121 Meyran Avenue, Pittsburgh, PA, 15213, USA.
Psychotic-like experiences (PLEs) -subclinical experiences or symptoms that resemble psychosis, such as hallucinations and delusional thoughts-often emerge during adolescence and are predictive of serious psychopathology. Understanding PLEs during adolescence is crucial due to co-occurring developmental changes in neural reward systems that heighten the risk for psychotic-related and affective psychopathology, especially in those with a family history of severe mental illness (SMI). We examined associations among PLEs, clinical symptoms, and neural reward function during this critical developmental period.
View Article and Find Full Text PDFJ Affect Disord
September 2025
Department of Psychiatry, University of North Carolina at Chapel Hill, United States of America.
Background: Perimenopausal onset depression (PO-MDD) is a common cause of distress and functional impairment, though efforts to describe its clinical symptomatology have been limited. We aimed to characterize affective and anxiety symptoms associated with PO-MDD, and to identify clinical correlates of distress, including anxiety, temperament and climacteric symptoms.
Methods: Baseline data from unmedicated women, ages 44-55, with PO-MDD (n = 49) and without PO-MDD (controls; n = 37) in the late-perimenopause (STRAW -1 criteria) recruited for two studies examining estrogen's effect on brain activation were included.
J Affect Disord
September 2025
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, 1845 N. Soto St., Los Angeles, CA, 90032, USA; Department of Psychology, University of Southern California, 3620 McClintock Ave., Los Angeles, CA, 90089, USA.
Introduction: Individuals with elevated depression symptoms experience low positive affect, high negative affect, and cognitive dysfunction. Affective and cognitive disruptions also occur during cigarette abstinence. This study examined whether depression symptom levels associate with affect and cognitive dysfunction during a cigarette quit attempt.
View Article and Find Full Text PDF